Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Corbus Pharmaceuticals Holdings (CRBP) EBITDA Margin (2016 - 2021)

Corbus Pharmaceuticals Holdings has reported EBITDA Margin over the past 7 years, most recently at 2239.62% for Q3 2021.

  • For Q3 2021, EBITDA Margin rose 59597.0% year-over-year to 2239.62%; the TTM value through Jun 2022 reached 35881.58%, down 3350157.0%, while the annual FY2021 figure was 6350.09%, 389388.0% down from the prior year.
  • EBITDA Margin for Q3 2021 was 2239.62% at Corbus Pharmaceuticals Holdings, up from 12533.18% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 95.17% in Q4 2019 and troughed at 13307.44% in Q2 2020.
  • A 5-year average of 3050.93% and a median of 1429.2% in 2018 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: surged 884691bps in 2019 and later plummeted -1331330bps in 2020.
  • Year by year, EBITDA Margin stood at 873.63% in 2017, then plummeted by -902bps to 8751.74% in 2018, then soared by 101bps to 95.17% in 2019, then plummeted by -1371bps to 1209.33% in 2020, then crashed by -85bps to 2239.62% in 2021.
  • Business Quant data shows EBITDA Margin for CRBP at 2239.62% in Q3 2021, 12533.18% in Q2 2021, and 2484.31% in Q1 2021.